Get startedLog in
    Picture of Ose Immunotherapeutics SA logo

    OSE — Ose Immunotherapeutics SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Ose ImmunotherapeuticS Enrols First Patient In Phase 2 Trial Testing Of OSE-127/S95011

    Picture of Ose Immunotherapeutics SA logoOse Immunotherapeutics SA
    21/12/2020 17:07
    Dec 21 (Reuters) - OSE IMMUNOTHERAPEUTICS SA  OSE.PA :
    * ANNOUNCES ENROLMENT OF FIRST PATIENT WITH ULCERATIVE
COLITIS IN
PHASE 2 TRIAL TESTING ANTI-IL-7 RECEPTOR ANTAGONIST
OSE-127/S95011

Source text for Eikon:  ID:nBw1Q9R09a 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Ose Immunotherapeutics SA

    See all news